222 related articles for article (PubMed ID: 12506023)
1. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20.
Sansonno D; De Re V; Lauletta G; Tucci FA; Boiocchi M; Dammacco F
Blood; 2003 May; 101(10):3818-26. PubMed ID: 12506023
[TBL] [Abstract][Full Text] [Related]
2. B-cell depletion in the treatment of mixed cryoglobulinemia.
Sansonno D; Tucci FA; Montrone M; Troiani L; Sansonno L; Gatti P; Lauletta G
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S116-21. PubMed ID: 17936212
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.
Petrarca A; Rigacci L; Caini P; Colagrande S; Romagnoli P; Vizzutti F; Arena U; Giannini C; Monti M; Montalto P; Matucci-Cerinic M; Bosi A; Laffi G; Zignego AL
Blood; 2010 Jul; 116(3):335-42. PubMed ID: 20308604
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
Cacoub P; Delluc A; Saadoun D; Landau DA; Sene D
Ann Rheum Dis; 2008 Mar; 67(3):283-7. PubMed ID: 17644544
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.
Roccatello D; Baldovino S; Rossi D; Mansouri M; Naretto C; Gennaro M; Cavallo R; Alpa M; Costanzo P; Giachino O; Mazzucco G; Sena LM
Nephrol Dial Transplant; 2004 Dec; 19(12):3054-61. PubMed ID: 15494358
[TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
Dammacco F; Tucci FA; Lauletta G; Gatti P; De Re V; Conteduca V; Sansonno S; Russi S; Mariggiò MA; Chironna M; Sansonno D
Blood; 2010 Jul; 116(3):343-53. PubMed ID: 20308602
[TBL] [Abstract][Full Text] [Related]
7. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab.
Petrarca A; Rigacci L; Monti M; Giannini C; Bernardi F; Caini P; Colagrande S; Bosi A; Laffi G; Zignego AL
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S129-33. PubMed ID: 17936214
[TBL] [Abstract][Full Text] [Related]
8. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.
Saadoun D; Resche Rigon M; Sene D; Terrier B; Karras A; Perard L; Schoindre Y; Coppéré B; Blanc F; Musset L; Piette JC; Rosenzwajg M; Cacoub P
Blood; 2010 Jul; 116(3):326-34; quiz 504-5. PubMed ID: 20439619
[TBL] [Abstract][Full Text] [Related]
9. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P
Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690
[TBL] [Abstract][Full Text] [Related]
10. Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment.
Stasi C; Triboli E; Arena U; Urraro T; Petrarca A; Gragnani L; Laffi G; Zignego AL
J Transl Med; 2014 Jan; 12():21. PubMed ID: 24456582
[TBL] [Abstract][Full Text] [Related]
11. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.
Roccatello D; Baldovino S; Rossi D; Giachino O; Mansouri M; Naretto C; Di Simone D; Francica S; Cavallo R; Alpa M; Napoli F; Sena LM
Clin Rev Allergy Immunol; 2008 Feb; 34(1):111-7. PubMed ID: 18270864
[TBL] [Abstract][Full Text] [Related]
12. [Current therapeutic strategies for HCV-associated cryoglobulinemia].
Iannuzzella F; Garini G
Reumatismo; 2008; 60(3):163-73. PubMed ID: 18854876
[TBL] [Abstract][Full Text] [Related]
13. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.
Saadoun D; Rosenzwajg M; Landau D; Piette JC; Klatzmann D; Cacoub P
Blood; 2008 Jun; 111(11):5334-41. PubMed ID: 18292291
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure.
Ghijsels E; Lerut E; Vanrenterghem Y; Kuypers D
Am J Kidney Dis; 2004 May; 43(5):e34-8. PubMed ID: 15112197
[TBL] [Abstract][Full Text] [Related]
15. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis.
Lamprecht P; Lerin-Lozano C; Merz H; Dennin RH; Gause A; Voswinkel J; Peters SO; Gutzeit O; Arlt AC; Solbach W; Gross WL
Ann Rheum Dis; 2003 Dec; 62(12):1230-3. PubMed ID: 14644867
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab in type II mixed cryoglobulinemia.
Zaja F; De Vita S; Mazzaro C; Sacco S; Damiani D; De Marchi G; Michelutti A; Baccarani M; Fanin R; Ferraccioli G
Blood; 2003 May; 101(10):3827-34. PubMed ID: 12560225
[TBL] [Abstract][Full Text] [Related]
17. Acute wrist and foot drop associated with hepatitis C virus related mixed cryoglobulinemia: rapid response to treatment with rituximab.
Uppal R; Charles E; Lake-Bakaar G
J Clin Virol; 2010 Jan; 47(1):69-71. PubMed ID: 19892591
[TBL] [Abstract][Full Text] [Related]
18. B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia.
Lake-Bakaar G; Jacobson I; Talal A
Clin Exp Immunol; 2012 Nov; 170(2):231-7. PubMed ID: 23039894
[TBL] [Abstract][Full Text] [Related]
19. Long-term remission with rituximab in a patient with severe hepatitis C virus-induced mixed cryoglobulinemia.
Fortea-Ormaechea JI; Lozano-Maya M; Adán-Merino L; Barrio-Antoranz J; Martín-Chavarri S; Corchete-Prats E; Martínez-Acebes E; Aldeguer-Martínez M
Rev Esp Enferm Dig; 2013 Sep; 105(8):490-3. PubMed ID: 24274448
[TBL] [Abstract][Full Text] [Related]
20. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
